Geneoscopy

Geneoscopy is a commercial-stage diagnostics company developing noninvasive tests for gastrointestinal diseases, anchored by its proprietary stool-derived eukaryotic RNA (seRNA) platform. The company achieved a major milestone in 2024 with FDA approval for its lead product, ColoSense, a colorectal cancer screening test, and subsequently secured a $105 million Series C financing round in early 2025. Founded in 2015 by sibling duo Andrew Barnell (MBA) and Dr. Erica Barnell (MD/PhD), Geneoscopy aims to address significant gaps in screening adherence and health equity by providing convenient, effective alternatives to invasive procedures like colonoscopies. The company is also exploring applications of its platform in inflammatory bowel disease and other GI conditions through research partnerships.

Proprietary stool-derived eukaryotic RNA (seRNA) platform that analyzes human RNA biomarkers from stool samples to provide a noninvasive snapshot of gastrointestinal tract health for disease detection and monitoring.

Geneoscopy competes in the noninvasive CRC screening market against dominant players like Exact Sciences (Cologuard) and newer entrants like Guardant Health (Shield). Competition is based on clinical performance (sensitivity/specificity), convenience, cost, and payer coverage. In the broader GI diagnostic space, it faces competition from endoscopic procedures and other biomarker tests.